BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23014266)

  • 1. Medical treatment of acquired nystagmus.
    Ehrhardt D; Eggenberger E
    Curr Opin Ophthalmol; 2012 Nov; 23(6):510-6. PubMed ID: 23014266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological treatment of nystagmus].
    Pieh-Beisse C; Lagrèze WA
    Ophthalmologe; 2011 Feb; 108(2):178-82. PubMed ID: 21253746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of vertigo/nystagmus/oscillopsia.
    Straube A
    Curr Opin Neurol; 2005 Feb; 18(1):11-4. PubMed ID: 15655396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nystagmus: an update on treatment in adults.
    Straube A
    Expert Opin Pharmacother; 2005 Apr; 6(4):583-90. PubMed ID: 15934884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacotherapy of central oculomotor disorders].
    Kalla R; Spiegel R; Wagner J; Rettinger N; Jahn K; Strupp M
    Nervenarzt; 2008 Dec; 79(12):1377-8, 1380-2, 1384-5. PubMed ID: 18633586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus.
    Kalla R; Glasauer S; Büttner U; Brandt T; Strupp M
    Brain; 2007 Sep; 130(Pt 9):2441-51. PubMed ID: 17664175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium channels, the cerebellum, and treatment for downbeat nystagmus.
    Leigh RJ
    Neurology; 2003 Jul; 61(2):158-9. PubMed ID: 12874391
    [No Abstract]   [Full Text] [Related]  

  • 8. 4-Aminopyridine suppresses positional nystagmus caused by cerebellar vermis lesion.
    Kremmyda O; Zwergal A; la Fougère C; Brandt T; Jahn K; Strupp M
    J Neurol; 2013 Jan; 260(1):321-3. PubMed ID: 23180177
    [No Abstract]   [Full Text] [Related]  

  • 9. 4-aminopyridine restores visual ocular motor function in upbeat nystagmus.
    Glasauer S; Kalla R; Büttner U; Strupp M; Brandt T
    J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):451-3. PubMed ID: 15716550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain.
    Kalla R; Glasauer S; Schautzer F; Lehnen N; Büttner U; Strupp M; Brandt T
    Neurology; 2004 Apr; 62(7):1228-9. PubMed ID: 15079036
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical use of 4-aminopyridine in patients with downbeat nystagmus.
    Domínguez-Durán E; Mármol-Szombathy I; Baños-Roldán Ú; Sánchez-Gómez S
    Acta Otorrinolaringol Esp (Engl Ed); 2020; 71(1):40-44. PubMed ID: 31078225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Periodic alternating nystagmus.
    DiBartolomeo JR; Yee RD
    Otolaryngol Head Neck Surg; 1988 Dec; 99(6):552-7. PubMed ID: 3148116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling drug modulation of nystagmus.
    Glasauer S; Rössert C
    Prog Brain Res; 2008; 171():527-34. PubMed ID: 18718349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.
    Hess E
    Neurology; 2011 Nov; 77(22):1996-7; author reply 1997. PubMed ID: 22123782
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus.
    Sprenger A; Zils E; Rambold H; Sander T; Helmchen C
    Ann N Y Acad Sci; 2005 Apr; 1039():395-403. PubMed ID: 15826992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of 3,4-diaminopyridine on positioning downbeat nystagmus in a circumscribed uvulo-nodular lesion.
    Helmchen C; Gottschalk S; Sander T; Trillenberg P; Rambold H; Sprenger A
    J Neurol; 2007 Aug; 254(8):1126-8. PubMed ID: 17410325
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of 3,4-diaminopyridine on the gravity dependence of ocular drift in downbeat nystagmus.
    Helmchen C; Sprenger A; Rambold H; Sander T; Kömpf D; Straumann D
    Neurology; 2004 Aug; 63(4):752-3. PubMed ID: 15326263
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacological advances in the treatment of neuro-otological and eye movement disorders.
    Strupp M; Brandt T
    Curr Opin Neurol; 2006 Feb; 19(1):33-40. PubMed ID: 16415675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study.
    Claassen J; Teufel J; Kalla R; Spiegel R; Strupp M
    J Neurol; 2013 Feb; 260(2):668-9. PubMed ID: 23183922
    [No Abstract]   [Full Text] [Related]  

  • 20. Update on the pharmacotherapy of cerebellar and central vestibular disorders.
    Kalla R; Teufel J; Feil K; Muth C; Strupp M
    J Neurol; 2016 Apr; 263 Suppl 1():S24-9. PubMed ID: 27083881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.